Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mast Therapeutics, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Over 18 years old.
Advanced cancer potentially sensitive to single agent docetaxel; ie.. locally advanced or metastatic breast cancer, locally advanced non-small cell lung cancer, hormone refractory metastatic prostate cancer, other tumor type with no standard treatment.
ECOG performance status of 0-2 and Karnofsky Score of 100-70.
You may not be if
Patients who have more effective therapy available than single agent docetaxel for the malignancy.
Pregnancy or lactation.
Intolerance to any antineoplastic agents belonging to the taxoid family.
Hypersensitivity to drugs formulated with polysorbate 80.
Active infection.
Prior anticancer therapy within 30 days prior to the first day of study treatment.
Participation in another experimental drug study within 30 days prior to the first day of study treatment.
Clareo Health | A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
